Results for tag: "Biosimilar Insulin"

In the biotechnology sector, the biosimilar insulin market has become an important focus due to the increasing prevalence of diabetes and the need for affordable therapeutic options. Biosimilar insulins are medical products that are highly similar to an already approved, original (also called 'reference' or 'innovator') insulin product, with no meaningful differences in terms of safety and effectiveness. The development of biosimilar insulins strives to provide more treatment options, enhance access to care, and reduce healthcare costs. The process includes rigorous comparative analytical studies, clinical studies, and regulatory assessments to ensure biosimilarity to the reference product. The emergence of biosimilars is reshaping the biotechnology landscape by introducing competition, fostering innovation, and potentially improving patient outcomes. Several companies have made their mark in the biosimilar insulin market. Among them, Biocon, partnered with Mylan, has developed and commercialized biosimilar insulin products. Sandoz, a division of Novartis, is also a key player, with a focus on expanding its biosimilar portfolio. Eli Lilly and Company, traditionally known for their original insulin products, are involved in the production of biosimilar insulins as well. Teva Pharmaceutical Industries and Geropharm are other active participants in the biosimilar insulin space, contributing to the growing availability of these therapeutic options. Show Less Read more